VIRGINIA RETIREMENT SYSTEMS ET Al Takes $99.23 Million Position in Bristol Myers Squibb Company $BMY

Key Points

• Virginia Retirement Systems disclosed a new $99.2 million position in Bristol Myers Squibb, purchasing 1.72 million shares and making BMY its 29th-largest holding. Institutional investors collectively own 76.41% of the company.
• Bristol Myers Squibb exceeded quarterly expectations with $2.04 in EPS versus a $1.60 consensus estimate and $12.97 billion in revenue, up 5.7% year over year. The company also maintains a $0.63 quarterly dividend, equivalent to a 3.8% yield.
• Analysts largely remain positive, with a “Moderate Buy” consensus and price targets reaching as high as $75, although investors face risks from legacy-drug declines, future Eliquis patent expiration and a pause in zola-cel trials following inflammatory safety concerns.

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,722,230 shares of the biopharmaceutical company's stock, valued at approximately $99,235,000. Bristol Myers Squibb makes up approximately 0.6% of VIRGINIA RETIREMENT SYSTEMS ET Al's investment portfolio, making the stock its 29th biggest position. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.08% of Bristol Myers Squibb as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. California State Teachers Retirement System lifted its position in Bristol Myers Squibb by 5,484.7% during the second quarter. California State Teachers Retirement System now owns 185,255,963 shares of the biopharmaceutical company's stock valued at $10,674,449,000 after buying an additional 181,938,762 shares during the period. Paralel Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $2,195,000. Ameritas Advisory Services LLC increased its stake in shares of Bristol Myers Squibb by 52.7% in the 2nd quarter. Ameritas Advisory Services LLC now owns 14,839 shares of the biopharmaceutical company's stock worth $855,000 after acquiring an additional 5,121 shares in the last quarter. Wedmont Private Capital increased its stake in shares of Bristol Myers Squibb by 12.1% in the 2nd quarter. Wedmont Private Capital now owns 19,243 shares of the biopharmaceutical company's stock worth $1,108,000 after acquiring an additional 2,073 shares in the last quarter. Finally, Kintra Wealth LLC lifted its position in Bristol Myers Squibb by 28.9% during the 2nd quarter. Kintra Wealth LLC now owns 6,821 shares of the biopharmaceutical company's stock valued at $393,000 after acquiring an additional 1,529 shares during the period. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $66.85 on Monday. The company has a market capitalization of $136.56 billion, a price-to-earnings ratio of 14.72, a price-to-earnings-growth ratio of 0.32 and a beta of 0.23. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The company's 50-day moving average is $62.92 and its 200 day moving average is $59.92.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm's revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a Phase 2 trial evaluating a therapy in depression, expanding its pipeline into a large potential market. Positive clinical progress could provide a new growth opportunity if the treatment demonstrates efficacy and safety. Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, roughly 3.7% forward dividend yield, strong margins and growth products that are offsetting declines in older medicines. These factors support the stock’s defensive and income-oriented appeal. Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
• Neutral Sentiment: Technical indicators have reportedly turned bullish, while RBC Capital maintained a Hold rating, indicating that analysts see some upside but remain cautious about the company’s outlook. Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
• Negative Sentiment: Bristol Myers Squibb paused enrollment in its zola-cel autoimmune cell-therapy trials after safety surveillance identified inflammatory side effects. Reports that the pause involved serious safety concerns raised questions about the program’s risk profile, development timeline and broader cell-therapy strategy. What Does Bristol Myers Squibb Trial Pause Mean For Its Pipeline?
• Negative Sentiment: The wider healthcare sector traded lower, adding industry-level pressure to BMY. Investors also continue to monitor legacy-drug declines, including Opdivo, and future Eliquis patent-expiry risks. Sector Update: Healthcare Stocks Decline Friday Afternoon

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares of the company's stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.05% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on BMY shares. Truist Financial restated a "buy" rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. TD Cowen began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "buy" rating for the company. Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. JPMorgan Chase & Co. upped their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Finally, Guggenheim reaffirmed a "buy" rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source